The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70317 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Julie Semenchuk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Adult CF Program, St. Michael's Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Lung Transplantation, Cystic Fibrosis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically changed the landscape of cystic fibrosis (CF) care, including in those who require lung transplantation. The objectives of the study were to describe the cohort demographics and outcomes of primary lung transplant recipients before and after the availability of ETI.
Methods
This is a descriptive study of lung transplants performed at the Toronto Lung Transplant Program for CF during two time periods: 2019 (pre‐ETI era) and 2021–2023 (post‐ETI era). All subjects were referred from the Adult CF program at St. Michael's Hospital, Toronto. Data were obtained from chart review and the Toronto Lung Transplant database. The Kaplan–Meier method was used to estimate survival probability at 1 year post‐transplant.
Results
There were 22 lung transplants performed in 2019 (19 [86.4%] primary and 3 [13.6%] re‐transplants) compared to 11 lung transplants (8 [72.7%] primary and 3 [27.3%] re‐transplants) in the post‐ETI era. In primary transplant recipients, median age was 29.4 years (Range 18.6–67.6 years) in 2019 compared to 30.0 years (Range 19.1–64.0 years) in 2021–2023. In the post‐ETI era, none of the individuals had a deltaF508 variant, compared to 84% in 2019. One‐year survival probability was lower in the post‐ETI era (62.5% vs. 84.2%, respectively).
Conclusion
Lung transplant recipients in the post‐ETI era were more complex with high‐risk characteristics and had worse post‐transplant outcomes. This study highlights the importance of further investigation to better understand the impact of ETI on transplant referral patterns, recipient characteristics, and post‐transplant outcomes in the CF population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adult CF Program, St. Michael's Hospital, Toronto, Ontario, Canada.
- Toronto Lung Transplant Program, University Health Network, Toronto, Ontario, Canada.
- Cystic Fibrosis Canada, Toronto, Ontario, Canada.
- Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Julie Semenchuk, Meghan Aversa
Zitieren
APA
Semenchuk, J., Tuff-Gordon, E., Ma, X., Sykes, J., Cheng, S. Y., Aversa, M., Chaparro, C., Tullis, E., & Stephenson, A. L. (2025). The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution. Clinical Transplantation. https://doi.org/10.1111/ctr.70317
Vancouver
Semenchuk J, Tuff-Gordon E, Ma X, Sykes J, Cheng SY, Aversa M, et al. The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution. Clinical Transplantation. 2025. doi:10.1111/ctr.70317
BibTeX
@article{Semenchuk2025,
author = {Semenchuk, Julie and Tuff-Gordon, Eliza and Ma, Xiayi and Sykes, Jenna and Cheng, Stephanie Y and Aversa, Meghan and Chaparro, Cecilia and Tullis, Elizabeth and Stephenson, Anne L},
title = {The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70317}
}
EUVIMED